​

Lexicon Pharmaceuticals (LXRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LXRX Stock Forecast

Lexicon Pharmaceuticals (LXRX) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 1076.47% increase from the last price of $0.51.

- $1 $2 $3 $4 $5 $6 High: $6 Avg: $6 Low: $6 Last Closed Price: $0.51

LXRX Stock Rating

Lexicon Pharmaceuticals stock's rating consensus is Hold, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (38.46%), 7 Hold (53.85%), 1 Sell (7.69%), and 0 Strong Sell (0.00%).

Hold
Total 13 1 7 5 0 Strong Sell Sell Hold Buy Strong Buy

LXRX Price Target Upside V Benchmarks

TypeNameUpside
StockLexicon Pharmaceuticals1076.47%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$6.00
Last Closing Price$0.51$0.51$0.51
Upside/Downside--1076.47%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25213--6
Mar, 25222--6
Feb, 25222--6
Jan, 25222--6
Dec, 24222--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 18, 2024Roanna RuizLeerink Partners$6.00$2.01198.51%1076.47%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 07, 2025Piper SandlerOverweightOverweighthold
Oct 23, 2024H.C. WainwrightBuyBuyhold
Oct 18, 2024Leerink PartnersOutperformOutperformhold
Oct 17, 2024Piper SandlerOverweightOverweighthold
Sep 27, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024H.C. WainwrightBuyBuyhold
Aug 02, 2024H.C. WainwrightBuyBuyhold
Jun 17, 2024H.C. WainwrightBuyinitialise
May 31, 2024Piper SandlerOverweightOverweighthold
Jul 01, 2022CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.63$-0.61$-0.62$-0.80$-0.63----
Avg Forecast$-0.74$-0.61$-0.56$-0.80$-0.68$-0.46$-0.41$-0.30$-0.08
High Forecast$-0.52$-0.43$-0.15$-0.78$-0.59$-0.32$-0.26$-0.18$-0.02
Low Forecast$-1.07$-0.87$-1.71$-0.81$-0.76$-0.67$-0.68$-0.39$-0.22
Surprise %-14.86%-10.71%--7.35%----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$24.00M$298.00K$139.00K$1.20M$31.08M----
Avg Forecast$156.75M$194.67K$137.00K$1.75M$11.13M$13.33M$26.92M$94.86M$188.72M
High Forecast$210.41M$261.29K$352.10K$1.87M$26.90M$29.25M$26.92M$235.47M$468.45M
Low Forecast$121.03M$150.31K$60.61K$1.62M$5.59M$5.45M$26.92M$37.10M$73.80M
Surprise %-84.69%53.08%1.46%-31.26%179.22%----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-70.18M$-88.27M$-103.13M$-177.12M$-200.40M----
Avg Forecast$-163.56M$-96.45M$-97.36M$-177.12M$-149.02M$-109.19M$-104.28M$-62.60M$-16.95M
High Forecast$-115.10M$-77.16M$-77.89M$-141.70M$-129.68M$-70.52M$-57.93M$-39.75M$-3.53M
Low Forecast$-236.33M$-115.74M$-116.83M$-212.54M$-168.35M$-147.86M$-150.62M$-85.46M$-49.62M
Surprise %-57.09%-8.48%5.92%-34.49%----

LXRX Forecast FAQ

Is Lexicon Pharmaceuticals stock a buy?

Lexicon Pharmaceuticals stock has a consensus rating of Hold, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 7 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Lexicon Pharmaceuticals is a neutral investment for most analysts.

What is Lexicon Pharmaceuticals's price target?

Lexicon Pharmaceuticals's price target, set by 13 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 1076.47% change from the previous closing price of $0.51.

How does Lexicon Pharmaceuticals stock forecast compare to its benchmarks?

Lexicon Pharmaceuticals's stock forecast shows a 1076.47% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Lexicon Pharmaceuticals over the past three months?

  • April 2025: 33.33% Strong Buy, 16.67% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Lexicon Pharmaceuticals’s EPS forecast?

Lexicon Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.46, marking a -26.98% decrease from the reported $-0.63 in 2024. Estimates for the following years are $-0.41 in 2026, $-0.3 in 2027, and $-0.08 in 2028.

What is Lexicon Pharmaceuticals’s revenue forecast?

Lexicon Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $13.33M, reflecting a -57.12% decrease from the reported $31.08M in 2024. The forecast for 2026 is $26.92M, followed by $94.86M for 2027, and $188.72M for 2028.

What is Lexicon Pharmaceuticals’s net income forecast?

Lexicon Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-109M, representing a -45.52% decrease from the reported $-200M in 2024. Projections indicate $-104M in 2026, $-62.603M in 2027, and $-16.953M in 2028.